ECSP22031077A - Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación - Google Patents
Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparaciónInfo
- Publication number
- ECSP22031077A ECSP22031077A ECSENADI202231077A ECDI202231077A ECSP22031077A EC SP22031077 A ECSP22031077 A EC SP22031077A EC SENADI202231077 A ECSENADI202231077 A EC SENADI202231077A EC DI202231077 A ECDI202231077 A EC DI202231077A EC SP22031077 A ECSP22031077 A EC SP22031077A
- Authority
- EC
- Ecuador
- Prior art keywords
- polysaccharide
- typhi
- methods
- preparation
- present disclosure
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 208000028774 intestinal disease Diseases 0.000 title 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 abstract 3
- 150000004676 glycans Chemical class 0.000 abstract 3
- 229920001282 polysaccharide Polymers 0.000 abstract 3
- 239000005017 polysaccharide Substances 0.000 abstract 3
- 241001467018 Typhis Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000008297 typhoid fever Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000005577 Gastroenteritis Diseases 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 abstract 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 abstract 1
- 208000037386 Typhoid Diseases 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación se refiere a nuevas composiciones de vacuna inmunogénicas monovalentes y multivalentes conjugadas de polisacárido-proteína que comprenden un polisacárido seleccionado de cepas de Salmonella serotipo S. typhi; S. paratifus A; S. typhimurium y S. enteritidis y métodos alternativos mejorados de fermentación de polisacáridos, purificación de polisacáridos, conjugación de polisacáridos y proteínas y formulación estable. La presente divulgación se refiere además a métodos para inducir una respuesta inmune en sujetos contra Salmonella typhi y enfermedades no relacionadas con typhi y/o para reducir o prevenir Salmonella typhi y enfermedades no relacionadas con typhi en sujetos que usan las composiciones descritas en este documento. La vacuna provoca anticuerpos bactericidas y es útil para la prevención de gastroenteritis, fiebre entérica y tifoidea.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921035435 | 2019-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22031077A true ECSP22031077A (es) | 2022-05-31 |
Family
ID=72659843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202231077A ECSP22031077A (es) | 2019-09-03 | 2022-04-01 | Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230149524A1 (es) |
EP (2) | EP4249061A3 (es) |
JP (1) | JP2022546763A (es) |
KR (2) | KR20220087437A (es) |
CN (1) | CN114728053A (es) |
AR (1) | AR119884A1 (es) |
AU (1) | AU2020343943A1 (es) |
BR (1) | BR112022003892A2 (es) |
CA (1) | CA3149972A1 (es) |
CO (1) | CO2022003789A2 (es) |
CR (1) | CR20220132A (es) |
EC (1) | ECSP22031077A (es) |
GB (2) | GB2603362A (es) |
IL (1) | IL291006A (es) |
JO (1) | JOP20200214A1 (es) |
MA (1) | MA56283A1 (es) |
MX (1) | MX2022002693A (es) |
PE (1) | PE20221442A1 (es) |
WO (1) | WO2021044436A2 (es) |
ZA (1) | ZA202203368B (es) |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
WO1998026799A1 (en) * | 1996-12-18 | 1998-06-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugate vaccine for salmonella paratyphi a |
AU771330B2 (en) | 1998-08-19 | 2004-03-18 | Baxter Healthcare Sa | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR101351870B1 (ko) | 2005-06-27 | 2014-02-17 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
CN103397065A (zh) | 2006-09-13 | 2013-11-20 | 雅培制药有限公司 | 细胞培养改良 |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
FR2938265B1 (fr) | 2008-11-12 | 2011-07-15 | Univ Claude Bernard Lyon | Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble |
JP5892944B2 (ja) * | 2009-12-17 | 2016-03-23 | フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー | コンジュゲートワクチンの製造における多糖の活性化のための化学試薬 |
US9011871B2 (en) * | 2011-11-07 | 2015-04-21 | University Of Maryland, Baltimore | Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease |
US9283270B2 (en) * | 2012-01-20 | 2016-03-15 | Serum Institute Of India Ltd. | Method for stabilization of biological molecules |
TR201900778T4 (tr) | 2012-01-30 | 2019-02-21 | Serum Institute Of India Private Ltd | İmmünojenik bileşim. |
CN102935226B (zh) * | 2012-11-16 | 2014-01-22 | 罗益(无锡)生物制药有限公司 | 伤寒甲型副伤寒结合疫苗及其制备方法 |
CN105744951B (zh) * | 2013-08-24 | 2021-03-16 | 巴拉特生物技术国际有限公司 | 细菌疫苗及其制备方法 |
CN104383532A (zh) * | 2014-12-02 | 2015-03-04 | 云南沃森生物技术股份有限公司 | 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法 |
EA039487B1 (ru) * | 2015-07-04 | 2022-02-01 | Бхарат Байотек Интернэшнл Лимитед | Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов |
WO2017187448A1 (en) * | 2016-04-25 | 2017-11-02 | National Institute Of Immunology | A novel conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate |
CA3032901A1 (en) | 2016-08-26 | 2018-03-01 | Serum Institute Of India Private Limited | Multivalent vaccine composition |
GEP20227408B (en) * | 2017-05-05 | 2022-08-25 | Serum Institute Of India Pvt Ltd | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
BR112020000999A2 (pt) | 2017-07-18 | 2020-07-14 | Serum Institute Of India Pvt Ltd. | composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
-
2019
- 2019-09-03 JO JOP/2020/0214A patent/JOP20200214A1/ar unknown
-
2020
- 2020-09-02 KR KR1020227011108A patent/KR20220087437A/ko unknown
- 2020-09-02 MA MA56283A patent/MA56283A1/fr unknown
- 2020-09-02 WO PCT/IN2020/050763 patent/WO2021044436A2/en active Application Filing
- 2020-09-02 BR BR112022003892A patent/BR112022003892A2/pt unknown
- 2020-09-02 AU AU2020343943A patent/AU2020343943A1/en active Pending
- 2020-09-02 CN CN202080074655.7A patent/CN114728053A/zh active Pending
- 2020-09-02 PE PE2022000363A patent/PE20221442A1/es unknown
- 2020-09-02 US US17/753,248 patent/US20230149524A1/en active Pending
- 2020-09-02 EP EP23184552.0A patent/EP4249061A3/en active Pending
- 2020-09-02 GB GB2204276.6A patent/GB2603362A/en active Pending
- 2020-09-02 KR KR1020247034650A patent/KR20240155975A/ko active Application Filing
- 2020-09-02 JP JP2022514468A patent/JP2022546763A/ja active Pending
- 2020-09-02 EP EP20781107.6A patent/EP4025246A2/en active Pending
- 2020-09-02 MX MX2022002693A patent/MX2022002693A/es unknown
- 2020-09-02 CR CR20220132A patent/CR20220132A/es unknown
- 2020-09-02 CA CA3149972A patent/CA3149972A1/en active Pending
- 2020-09-02 GB GB2412329.1A patent/GB2629746A/en active Pending
- 2020-09-03 AR ARP200102458A patent/AR119884A1/es unknown
-
2022
- 2022-03-01 IL IL291006A patent/IL291006A/en unknown
- 2022-03-22 ZA ZA2022/03368A patent/ZA202203368B/en unknown
- 2022-03-29 CO CONC2022/0003789A patent/CO2022003789A2/es unknown
- 2022-04-01 EC ECSENADI202231077A patent/ECSP22031077A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3149972A1 (en) | 2021-03-11 |
WO2021044436A2 (en) | 2021-03-11 |
JP2022546763A (ja) | 2022-11-08 |
WO2021044436A3 (en) | 2021-05-27 |
CR20220132A (es) | 2022-05-06 |
EP4025246A2 (en) | 2022-07-13 |
CN114728053A (zh) | 2022-07-08 |
EP4249061A3 (en) | 2023-11-15 |
KR20240155975A (ko) | 2024-10-29 |
GB202204276D0 (en) | 2022-05-11 |
PE20221442A1 (es) | 2022-09-21 |
AR119884A1 (es) | 2022-01-19 |
BR112022003892A2 (pt) | 2022-05-24 |
GB2629746A (en) | 2024-11-06 |
US20230149524A1 (en) | 2023-05-18 |
GB2603362A (en) | 2022-08-03 |
CO2022003789A2 (es) | 2022-04-19 |
KR20220087437A (ko) | 2022-06-24 |
JOP20200214A1 (ar) | 2021-03-03 |
IL291006A (en) | 2022-05-01 |
EP4249061A2 (en) | 2023-09-27 |
MA56283A1 (fr) | 2023-01-31 |
MX2022002693A (es) | 2022-07-12 |
AU2020343943A1 (en) | 2022-03-24 |
ZA202203368B (en) | 2022-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001478A1 (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos. | |
CO2017011245A2 (es) | Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos | |
DOP2021000127A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso | |
TW200722101A (en) | Novel composition | |
BR112012022669A2 (pt) | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. | |
BRPI0620163B8 (pt) | composição imunogênica, vacina, processo para produzir a vacina, e, uso da composição imunogênica ou vacina | |
BR112014018815A8 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
ECSP22031077A (es) | Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación | |
WO2010083477A3 (en) | Broad spectrum vaccine against non-typhoidal salmonella | |
MX2023005221A (es) | Composiciones inmunogenicas para uso en vacunas neumococicas. | |
EA201301213A1 (ru) | Экзополисахарид бактерии shigella sonnei, способ его получения и включающие его вакцина и фармацевтическая композиция | |
MX2015017677A (es) | Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas. | |
AR104514A1 (es) | Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos | |
EA202191647A1 (ru) | Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения | |
SG160386A1 (en) | Novel composition | |
Haroun et al. | The Enhancement of the Pasteurella's Bacterin by Propolis Extracts |